Core Insights - Crucial Innovations Corp. (CINV) has launched a new patient-facing brand called 4TP, aimed at providing consistent and ethically produced Cannabis-Based Products for Medicinal Use (CBPMs) across the UK and Europe [1][9] - The launch of 4TP is part of CINV's Plant-to-Patient operating model, which integrates regulated cultivation, pharmaceutical-grade processing, and clinician-led patient access into a single framework [2][3] Group 1: Product and Model Overview - 4TP is designed to bridge the gap between plant science and patient care, offering structured educational materials that facilitate informed discussions between patients and prescribers [4][5] - The Plant-to-Patient model emphasizes a transparent medical value chain, moving away from commodity cannabis towards precision therapeutic solutions [3][8] Group 2: Quality and Transparency - All 4TP cultivars are produced in SOP-driven, audited environments, focusing on terpene expression, batch consistency, and documented process control to reduce variability and support repeatable outcomes [6][7] - The brand promotes traceability and stability at the product level, enhancing prescriber confidence and providing patients with clarity regarding the production and governance of their medicine [7][8] Group 3: Strategic Goals - The launch of 4TP is a strategic step for CINV to build scalable, regulator-ready medical platforms that can be replicated across jurisdictions, reflecting capital efficiency and operational repeatability [9] - CINV aims to deepen confidence across clinics, pharmacies, and prescribing networks by reinforcing pharmaceutical logic, quality systems, and educational support through the 4TP brand [8][9]